Evidence map›Paper›PMID 29045498›Full record

ArticlePloS one2017

Novel drug targets in cell wall biosynthesis exploited by gene disruption in Pseudomonas aeruginosa.

Ayssar A Elamin, Susanne Steinicke, Wulf Oehlmann, Yvonne Braun, Hanaa Wanas, Eduard A Shuralev, Carmen Huck, Marko Maringer, Manfred Rohde, Mahavir Singh

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. A Systematic Strategy to Find Potential Therapeutic Targets forFrontiers in molecular biosciences · 2021
    Article
  9. Toward a structome of Acinetobacter baumannii drug targets.Protein science : a publication of the Protein Society · 2020
    Article
  10. Article
  11. Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens.Microbiology and molecular biology reviews : MMBR · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Ayssar A ElaminLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Susanne SteinickeLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Wulf OehlmannLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Yvonne BraunLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Hanaa WanasLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Eduard A ShuralevInstitute of Environmental Sciences, Kazan Federal University, Kazan, Tatarstan, Russian Federation.ORCID http://orcid.org/0000-0003-0650-3090
Carmen Huckmfd Diagnostics GmbH, Wendelsheim, Germany.
Marko Maringermfd Diagnostics GmbH, Wendelsheim, Germany.
Manfred RohdeCentral Facility for Microscopy, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Mahavir SinghLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.ORCID http://orcid.org/0000-0003-0273-8394
Lionex (Germany) · DECS Diagnostics · DEHelmholtz Centre for Infection Research · DEKazan Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For clinicians, Pseudomonas aeruginosa is a nightmare pathogen that is one of the top three causes of opportunistic human infections. Therapy of P. aeruginosa infections is complicated due to its natural high intrinsic resistance to antibiotics. Active efflux and decreased uptake of drugs due to cell wall/membrane permeability appear to be important issues in the acquired antibiotic tolerance mechanisms. Bacterial cell wall biosynthesis enzymes have been shown to be essential for pathogenicity of Gram-negative bacteria. However, the role of these targets in virulence has not been identified in P. aeruginosa. Here, we report knockout (k.o) mutants of six cell wall biosynthesis targets (murA, PA4450; murD, PA4414; murF, PA4416; ppiB, PA1793; rmlA, PA5163; waaA, PA4988) in P. aeruginosa PAO1, and characterized these in order to find out whether these genes and their products contribute to pathogenicity and virulence of P. aeruginosa. Except waaA k.o, deletion of cell wall biosynthesis targets significantly reduced growth rate in minimal medium compared to the parent strain. The k.o mutants showed exciting changes in cell morphology and colonial architectures. Remarkably, ΔmurF cells became grossly enlarged. Moreover, the mutants were also attenuated in vivo in a mouse infection model except ΔmurF and ΔwaaA and proved to be more sensitive to macrophage-mediated killing than the wild-type strain. Interestingly, the deletion of the murA gene resulted in loss of virulence activity in mice, and the virulence was restored in a plant model by unknown mechanism. This study demonstrates that cell wall targets contribute significantly to intracellular survival, in vivo growth, and pathogenesis of P. aeruginosa. In conclusion, these findings establish a link between cell wall targets and virulence of P. aeruginosa and thus may lead to development of novel drugs for the treatment of P. aeruginosa infection.

Indexed as

Gene Knockdown TechniquesAnimalsAnti-Bacterial AgentsBiosynthetic PathwaysCell WallColony Count, MicrobialDNA, BacterialExtracellular SpaceFemaleGenes, BacterialGenetic VectorsLactucaLipopolysaccharidesLungMacrophagesMiceAnti-Bacterial AgentsDNA, BacterialLipopolysaccharidesPeptidoglycan

Identifiers

PMID29045498
PMCPMC5646862
OpenAlexW2766187115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.